TWI265931B - Composition and method for inhibiting platelet aggregation - Google Patents
Composition and method for inhibiting platelet aggregationInfo
- Publication number
- TWI265931B TWI265931B TW090120539A TW90120539A TWI265931B TW I265931 B TWI265931 B TW I265931B TW 090120539 A TW090120539 A TW 090120539A TW 90120539 A TW90120539 A TW 90120539A TW I265931 B TWI265931 B TW I265931B
- Authority
- TW
- Taiwan
- Prior art keywords
- platelet aggregation
- polyphosphates
- directed
- composition
- receptor antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/643,138 US7018985B1 (en) | 2000-08-21 | 2000-08-21 | Composition and method for inhibiting platelet aggregation |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI265931B true TWI265931B (en) | 2006-11-11 |
Family
ID=24579508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW090120539A TWI265931B (en) | 2000-08-21 | 2001-08-21 | Composition and method for inhibiting platelet aggregation |
Country Status (12)
Country | Link |
---|---|
US (2) | US7018985B1 (zh) |
EP (1) | EP1311525A2 (zh) |
JP (1) | JP2004521074A (zh) |
KR (1) | KR20040014934A (zh) |
CN (1) | CN100465186C (zh) |
AR (1) | AR032631A1 (zh) |
AU (2) | AU2001285470B2 (zh) |
BR (1) | BR0113402A (zh) |
CA (1) | CA2420179A1 (zh) |
MX (1) | MXPA03001518A (zh) |
TW (1) | TWI265931B (zh) |
WO (1) | WO2002016381A2 (zh) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6864243B1 (en) * | 2000-05-12 | 2005-03-08 | Inspire Pharmaceuticals, Inc. | Method for treating retinal degeneration with purinergic receptor agonists |
US7452870B2 (en) | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
US7132408B2 (en) * | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
US7084128B2 (en) * | 2002-01-18 | 2006-08-01 | Inspire Pharmaceuticals, Inc. | Method for reducing intraocular pressure |
EP1348466A3 (en) * | 2002-02-01 | 2003-10-29 | Inspire Pharmaceuticals, Inc. | Method for treating pain with adenosine-tetraphosphates |
US7435724B2 (en) * | 2002-02-27 | 2008-10-14 | Inspire Pharmaceutical, Inc. | Degradation-resistant mononucleoside phosphate compounds |
US7241282B2 (en) * | 2002-11-08 | 2007-07-10 | The Brigham And Women's Hospital, Inc. | Compositions and methods for prolonging survival of platelets |
ES2586668T3 (es) | 2003-05-30 | 2016-10-18 | Gilead Pharmasset Llc | Análogos de nucleósidos fluorados modificados |
EP1685135B1 (en) | 2003-10-21 | 2010-05-26 | Inspire Pharmaceuticals, Inc. | TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION |
US7749981B2 (en) | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
US7335648B2 (en) | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
US7504497B2 (en) | 2003-10-21 | 2009-03-17 | Inspire Pharmaceuticals, Inc. | Orally bioavailable compounds and methods for inhibiting platelet aggregation |
WO2005041872A2 (en) * | 2003-10-22 | 2005-05-12 | University Of Rochester | Use of peroxisome proliferator-activated receptor gamma (pparϝ) and/or retinoic acid receptor (rxr) agonists to inhibit platelet functions |
EP1750740A4 (en) | 2004-05-06 | 2009-06-10 | Molichem Medicines Inc | TREATMENT OF MEMBRANE-ASSOCIATED DISEASES AND DISORDERS USING COMPOSITIONS CONTAINING LANTIBIOTICS |
EP1753445A4 (en) | 2004-05-06 | 2009-05-20 | Molichem Medicines Inc | TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS |
CN101023094B (zh) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
AU2005282449B2 (en) * | 2004-09-07 | 2011-07-14 | Velico Medical, Inc. | Apparatus for prolonging survival of platelets |
MX2007003085A (es) * | 2004-09-14 | 2007-08-02 | Pharmasset Inc | Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados. |
CA2626363A1 (en) * | 2004-10-15 | 2006-04-27 | Zymequest, Inc. | Compositions and methods for prolonging survival of platelets |
AU2006204159A1 (en) * | 2005-01-06 | 2006-07-13 | Astrazeneca Ab | Novel pyridine compounds |
EP1863826A1 (en) * | 2005-03-30 | 2007-12-12 | Inspire Pharmaceuticals, Inc. | Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles |
US7932376B2 (en) | 2005-05-05 | 2011-04-26 | Inspire Pharmaceuticals, Inc. | Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation |
AU2006267148A1 (en) * | 2005-07-13 | 2007-01-18 | Astrazeneca Ab | New pyridine analogues |
ITRM20050391A1 (it) * | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione. |
WO2007020935A1 (ja) * | 2005-08-17 | 2007-02-22 | Ono Pharmaceutical Co., Ltd. | P2y12受容体および/またはp2y14受容体ブロッカーを含有してなる疼痛治療剤 |
JP5552231B2 (ja) * | 2005-10-14 | 2014-07-16 | ベリコ メディカル インコーポレイティッド | 血小板の生存延長のための組成物および方法 |
GB0525970D0 (en) | 2005-12-21 | 2006-02-01 | Secr Defence | Supramolecular polymers |
WO2007140333A2 (en) * | 2006-05-26 | 2007-12-06 | Inspire Pharmaceuticals, Inc. | Mononucleoside phosphonate compounds |
TW200815426A (en) * | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
JP2009542642A (ja) * | 2006-07-04 | 2009-12-03 | アストラゼネカ アクチボラグ | 新規ピリジン類似体 |
WO2008004943A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | New pyridine analogues |
EP2041112A1 (en) * | 2006-07-04 | 2009-04-01 | Astra Zeneca AB | New pyridine analogues |
TW200811133A (en) * | 2006-07-04 | 2008-03-01 | Astrazeneca Ab | New pyridine analogues III 334 |
CL2008000091A1 (es) * | 2007-01-12 | 2008-09-05 | Astrazeneca Ab | Compuestos derivados de piridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del trastorno de agregacion plaquetaria. |
UY30867A1 (es) * | 2007-01-12 | 2008-09-02 | Astrazeneca Ab | Nuevos analogos de piridina vii 543 |
US20080200448A1 (en) * | 2007-01-12 | 2008-08-21 | Astrazeneca Ab | New Pyridine Analogues VIII 518 |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
TW200902513A (en) * | 2007-07-13 | 2009-01-16 | Astrazeneca Ab | New pyridine analogues |
DK2225253T3 (da) * | 2007-11-29 | 2012-08-27 | Actelion Pharmaceuticals Ltd | Phosphonsyrederivater og deres anvendelse som p2y12- receptorantagonister |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
WO2010048341A1 (en) * | 2008-10-22 | 2010-04-29 | Inspire Pharmaceuticals, Inc. | Method for treating cystic fibrosis |
CA2747188C (en) * | 2008-11-20 | 2017-06-13 | Glsynthesis Inc. | Antithrombotic diadenosine tetraphosphates and related analogs |
EP2376514A2 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nucleoside analogs |
MX2011006891A (es) | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
NZ593647A (en) | 2008-12-23 | 2013-08-30 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
AU2011235112B2 (en) | 2010-03-31 | 2015-07-09 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
US9156873B2 (en) | 2010-04-28 | 2015-10-13 | Isis Pharmaceuticals, Inc. | Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom |
AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
WO2013033178A1 (en) | 2011-08-30 | 2013-03-07 | University Of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
NZ716840A (en) | 2013-08-27 | 2017-06-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
CN103772461A (zh) * | 2014-01-06 | 2014-05-07 | 南京正科制药有限公司 | 一种坎格雷洛晶型ⅰ |
EP3849992A4 (en) | 2018-09-11 | 2022-06-29 | Risen (Suzhou) Pharma Tech Co., Ltd. | Cd73 inhibitors and pharmaceutical uses thereof |
US11530234B2 (en) | 2018-09-11 | 2022-12-20 | Risen (Suzhou) Pharma Tech Co., Ltd. | CD73 inhibitors and pharmaceutical uses thereof |
CN117700468B (zh) * | 2024-02-05 | 2024-05-03 | 深圳赛陆医疗科技有限公司 | 一种核苷酸类似物的制备方法 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3321462A (en) * | 1963-07-15 | 1967-05-23 | Syntex Corp | Process for the preparation of nucleoside polyphosphates |
GB1407903A (en) | 1973-03-21 | 1975-10-01 | Ici Ltd | Nucleotide derivatives |
JPS5973524A (ja) | 1982-10-21 | 1984-04-25 | Meito Sangyo Kk | 血栓性疾患処置剤 |
WO1989004321A1 (en) | 1987-11-05 | 1989-05-18 | The Worcester Foundation For Experimental Biology | Diadenosine 5', 5'''-p1, p4-tetraphosphate and analogs thereof as antithrombotic agents |
US5049550A (en) | 1987-11-05 | 1991-09-17 | Worcester Foundation For Experimental Biology | Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents |
GB9015684D0 (en) | 1990-07-17 | 1990-09-05 | Medical Res Council | Synthesis and uses of spin labelled ribonucleosides and ribonucleotides |
NZ239846A (en) | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
WO1992017488A1 (en) | 1991-04-06 | 1992-10-15 | Fisons Plc | Atp analogues |
US5654285A (en) | 1991-04-06 | 1997-08-05 | Astra Pharmaceuticals Limited | ADP and ATP analogues, process for making and administration to inhibit ADP-induced platelet aggregation |
US5292498A (en) | 1991-06-19 | 1994-03-08 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
ATE159950T1 (de) | 1993-02-10 | 1997-11-15 | Astra Pharma Prod | N-alkyl-2-substituierte atp-analoge |
AU7965694A (en) | 1993-10-15 | 1995-05-04 | Curators Of The University Of Missouri, The | Dna encoding the human p2u receptor and null cells expressing p2u receptors |
US5814609A (en) * | 1993-10-22 | 1998-09-29 | University Of Southern California | Compositions containing a disintegrin and methods for its use in preventing metastasis and other conditions |
US5656256A (en) | 1994-12-14 | 1997-08-12 | The University Of North Carolina At Chapel Hill | Methods of treating lung disease by an aerosol containing benzamil or phenamil |
EP0796098A4 (en) | 1994-12-22 | 1998-04-29 | Smithkline Beecham Corp | FIBRINOGEN RECEPTOR ANTAGONISTS |
US5635160A (en) | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
BR9609467A (pt) | 1995-07-11 | 1999-03-02 | Astra Pharma Prod | Composto uso de um composto composição farmacéutica e processos para preparação de um composto e tratamento de distúrbios de agregação planquetária |
US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
JP3519199B2 (ja) | 1996-02-06 | 2004-04-12 | 株式会社ソニー・コンピュータエンタテインメント | 画像生成装置 |
CN1229114C (zh) | 1996-03-27 | 2005-11-30 | 印斯拜尔药品股份有限公司 | 用三磷酸尿苷和相关化合物治疗纤毛运动障碍的方法 |
US5837861A (en) | 1997-02-10 | 1998-11-17 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency |
US5900407A (en) | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
US5681823A (en) | 1996-05-02 | 1997-10-28 | Prp Inc. | P1, P4 -dithio-P2 -P3 -monochloromethylene 5', 5'"-diadenosine P1, P4 -tetraphosphate as antithrombotic agent |
US5968913A (en) | 1996-07-03 | 1999-10-19 | Inspire Pharmaceuticals, Inc. | Pharmaceutical compositions of uridine triphosphate |
US5789391A (en) | 1996-07-03 | 1998-08-04 | Inspire Pharmaceuticals, Inc. | Method of treating sinusitis with uridine triphosphates and related compounds |
US5962432A (en) | 1996-07-03 | 1999-10-05 | Inspire Pharmaceuticals, Inc. | Sterilized, isotonic and pH-adjusted pharmaceutical formulation of uridine triphosphate |
US5763447C1 (en) | 1996-07-23 | 2002-05-07 | Inspire Pharmaceuticals | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds |
WO1998015835A1 (en) | 1996-10-08 | 1998-04-16 | Inspire Pharmaceuticals, Inc. | Method of early lung cancer detection via sputum induction and analysis of sputum to detect cancer associated substances |
US6159952A (en) | 1996-11-07 | 2000-12-12 | Inspire Pharmaceuticals, Inc. | Method of treating bronchitis with uridine triphosphate and related compounds |
EP0946561B1 (en) | 1996-12-20 | 2002-02-13 | AstraZeneca AB | Triazolo(4,5-d)pyrimidinyl derivatives and their use as medicaments |
NZ337225A (en) | 1997-02-06 | 2002-03-28 | Inspire Pharmaceuticals Inc | Dinucleotides useful for treating chronic pulmonary obstructive disorder |
SE9702774D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
US6462028B2 (en) | 1997-07-25 | 2002-10-08 | Inspire Pharmaceuticals, Inc. | Method of promoting cervical and vaginal secretions |
BRPI9810436B1 (pt) | 1997-07-25 | 2015-12-29 | Inspire Pharmaceuticals Inc | processo para a produção em larga escala de di (5'-tetrafosfato de uridina) e sais do mesmo |
CN1268056A (zh) | 1997-08-29 | 2000-09-27 | 查珀尔希尔北卡罗来纳大学 | 尿苷5’-二磷酸酯及其类似物在治疗肺疾病中的应用 |
US6528640B1 (en) | 1997-11-05 | 2003-03-04 | Ribozyme Pharmaceuticals, Incorporated | Synthetic ribonucleic acids with RNAse activity |
WO1999061012A2 (en) | 1998-05-22 | 1999-12-02 | Inspire Pharmaceuticals, Inc. | Therapeutic dinucleotide and derivatives |
SE9804175D0 (sv) | 1998-12-02 | 1998-12-02 | Astra Pharma Prod | New assay |
TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
CA2355227A1 (en) | 1998-12-23 | 2000-07-06 | Richard C. Boucher, Jr. | Targeted gene transfer using g protein coupled receptors |
DE60015734D1 (de) | 1999-02-26 | 2004-12-16 | Inspire Pharmaceuticals Durham | Verwendung von dinukleotidtriphosphaten, cytidindiphosphaten und adenindiphosphaten zur herstellung einer pharmazeutischen zubereitung zur förderung der schleimauthydratation |
SE9903290D0 (sv) | 1999-09-15 | 1999-09-15 | Astra Pharma Prod | Novel compounds |
SE9904129D0 (sv) | 1999-11-15 | 1999-11-15 | Astra Pharma Prod | Novel compounds |
SE9904377D0 (sv) | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
-
2000
- 2000-08-21 US US09/643,138 patent/US7018985B1/en not_active Expired - Fee Related
-
2001
- 2001-08-20 MX MXPA03001518A patent/MXPA03001518A/es active IP Right Grant
- 2001-08-20 AU AU2001285470A patent/AU2001285470B2/en not_active Ceased
- 2001-08-20 BR BR0113402-7A patent/BR0113402A/pt not_active IP Right Cessation
- 2001-08-20 CN CNB018166679A patent/CN100465186C/zh not_active Expired - Fee Related
- 2001-08-20 CA CA002420179A patent/CA2420179A1/en not_active Abandoned
- 2001-08-20 JP JP2002521478A patent/JP2004521074A/ja not_active Withdrawn
- 2001-08-20 WO PCT/US2001/041818 patent/WO2002016381A2/en active Search and Examination
- 2001-08-20 KR KR10-2003-7002585A patent/KR20040014934A/ko not_active Application Discontinuation
- 2001-08-20 EP EP01964633A patent/EP1311525A2/en not_active Withdrawn
- 2001-08-20 AU AU8547001A patent/AU8547001A/xx active Pending
- 2001-08-21 US US09/934,970 patent/US7101860B2/en not_active Expired - Fee Related
- 2001-08-21 TW TW090120539A patent/TWI265931B/zh not_active IP Right Cessation
- 2001-08-21 AR ARP010103990A patent/AR032631A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR032631A1 (es) | 2003-11-19 |
AU2001285470B2 (en) | 2007-01-25 |
KR20040014934A (ko) | 2004-02-18 |
BR0113402A (pt) | 2005-05-31 |
WO2002016381A2 (en) | 2002-02-28 |
US7018985B1 (en) | 2006-03-28 |
CA2420179A1 (en) | 2002-02-28 |
US20020052337A1 (en) | 2002-05-02 |
CN1501940A (zh) | 2004-06-02 |
EP1311525A2 (en) | 2003-05-21 |
US7101860B2 (en) | 2006-09-05 |
AU8547001A (en) | 2002-03-04 |
JP2004521074A (ja) | 2004-07-15 |
MXPA03001518A (es) | 2004-07-30 |
WO2002016381B1 (en) | 2002-08-15 |
WO2002016381A3 (en) | 2002-05-10 |
CN100465186C (zh) | 2009-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI265931B (en) | Composition and method for inhibiting platelet aggregation | |
WO2005097814A3 (en) | Composition and method for inhibiting platelet aggregation | |
WO2006119507A3 (en) | Non-nucleotide composition and method for inhibiting platelet aggregation | |
MY132073A (en) | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | |
MXPA02012034A (es) | Derivados de tiofeno utiles como agentes anticancerosos. | |
NO20011739D0 (no) | Quinazolinderivater | |
CY1111951T1 (el) | Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου | |
TWI265928B (en) | A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw | |
SE0104334D0 (sv) | Therapeutic agents | |
BRPI0518068A (pt) | composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada | |
ES2150489T3 (es) | 1-amidinofenil-pirrolidonas, -piperidinonas, -azetinonas como inhibidores de la agregacion de plaquetas. | |
WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
NO20003399L (no) | <Alfa>-amionoamidderivater som er nyttige som smertestillende midler | |
EP0726267A4 (en) | CHINAZOLIN DERIVATIVE | |
DE602004027409D1 (de) | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation | |
IL137266A0 (en) | Heterocyclic chemokine receptor antagonists and pharmaceutical compositions containing the same | |
GR3034650T3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
WO2003049676A3 (en) | Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer | |
IL134894A (en) | 2-substituted-1,3,4,5-tetrahydro-2h-gamma-carbolines, their preparation and pharmaceutical compositions containing them | |
PL344056A1 (en) | Piperididinyl and n-amidinopiperidinyl derivatives | |
BR0207829A (pt) | Composto de carbamato para uso na prevenção ou tratamento de distúrbios psicóticos | |
TW200510395A (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
BRPI0415546A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios | |
PL1684763T3 (pl) | 6-arylo-7-halogeno-imidazo[1,2-a]pirymidyny jako środki przeciwnowotworowe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |